IP Library Granted Patent US 11,879,009
Granted Patent B2
US 11,879,009 · App. 17/738,191 · Granted Jan 23, 2024

Multifunctional protein molecules comprising decorin and use thereof

Inventor: Gregory T. Bleck (Cross Plains, WI)
Assignee: CATALENT PHARMA SOLUTIONS, LLC
C07K16/22A61P35/00C07K14/4725C07K16/2818C07K16/2827C07K2317/24C07K2317/56
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,879,009
App. No.
17/738,191
Granted
Jan 23, 2024
Kind
B2
Abstract

The present invention relates to multifunctional protein molecules comprising decorin and uses thereof. In particular, the present invention relates to multifunctional protein molecules comprising decorin and a targeting polypeptide such as an antibody and methods of their production and uses thereof.

Claims (7)

1. A method of inhibiting a target protein and a signaling molecule in a cell, comprising:

contacting the cell with a multifunctional protein molecule comprising at least one decorin molecule having at least 95% sequence identity to SEQ ID NO:7 linked to an antibody molecule selected from the group consisting of bevacizumab, ranibizumab, ipilimumab, atezolizumab, avelumab, durvalumab, nivolumab and pembrolizumab under conditions such that at least one activity of the target protein and at least one activity of a signaling protein are inhibited in the cell, wherein the target protein is selected from the group consisting of VEGF-1, PD-1, PD-L1, and CTLA and wherein the signaling protein is selected from the group consisting of Transforming Growth Factor-β (TGF-β), Connective Tissue Growth Factor (CTGF), Platelet-Derived Growth Factor (PDGF), Vascular Endothelial Growth Factor Receptor 2 (VEGFR2), Hepatocyte Growth Factor Receptor (HGFR), Insulin-like Growth Factor 1 Receptor (IGF-1R), epidermal growth factor receptors (EGFRs), myostatin and C1q.

2. The method of claim 1 , wherein the cell is in vitro or in vivo.

3. The method of claim 1 , wherein the cell is in a subject.

4. The method of claim 1 , wherein the contacting results in inhibition of an activity selected from the group consisting of angiogenesis, PD-1 activity, PD-L1 activity, and CTLA-4 activity.

5. The method of claim 1 , wherein the cell is a cancer cell selected from the group consisting of lung cancer, colorectal cancer, liver cancer, breast cancer, kidney cancer, cervical cancer, ovarian cancer, and glioblastoma cells.

6. The method of claim 1 , wherein the signaling protein is Transforming Growth Factor-β (TGF-β).

Assignments (2)
SECURITY INTEREST Recorded Dec 19, 2024
From: CATALENT CTS (KANSAS CITY), LLC; REDWOOD BIOSCIENCE, INC.; R.P. SCHERER TECHNOLOGIES, LLC; CATALENT WELLNESS, LLC; CATALENT PHARMA SOLUTIONS, INC.; CATALENT WELLNESS NEW JERSEY, LLC; CATALENT MARYLAND, INC.; CATALENT GREENVILLE, INC.; CATALENT MICRON TECHNOLOGIES, INC.; CATALENT SAN DIEGO, INC.; CATALENT WELLNESS VIRGINIA, LLC; CATALENT USA PACKAGING, LLC; CATALENT PHARMA SOLUTIONS, LLC
To: ARES CAPITAL CORPORATION, AS COLLATERAL AGENT
Reel/Frame 069743/0458 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 3, 2022
From: BLECK, GREGORY T.
To: CATALENT PHARMA SOLUTIONS, LLC
Reel/Frame 060099/0623 →